A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.
Himisha BeltranClara OromendiaDaniel C DanilaBruce MontgomeryChristopher HoimesRussell Z SzmulewitzUlka VaishampayanAndrew J ArmstrongMark SteinJacek PinskiJuan M MosqueraVerena SailerRohan BarejaAlessandro RomanelNaveen GumpeniAndrea SbonerEtienne DardenneLoredana PucaDavide PrandiMark A RubinHoward I ScherDavid S RickmanFrancesca DemichelisDavid M NanusKarla V BallmanScott T TagawaPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2018)
Although the study did not meet its primary endpoint, a subset of patients with advanced prostate cancer and molecular features supporting Aurora-A and N-myc activation achieved significant clinical benefit from single-agent alisertib.